Pharmacyclics Inc (PCYC) 261.25 $PCYC Market overview -

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pharmacyclics Inc (PCYC) 261.25 $PCYC

Market overview - Global Pharmacyclics, Inc. Market Report Product Pipeline Review 2015 - By Acute Market Reports
M2 - Fri Feb 05, 7:02AM CST
'PHARMACYCLICS, INC. - Product Pipeline Review - 2015', provides an overview of the PHARMACYCLICS, INC.'s pharmaceutical research and development focus.
PCYC: 261.25 (+1.70)

Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
PCYC: 261.25 (+1.70), AMPE: 0.96 (-0.03), GSK: 45.25 (+0.18), MEIP: 1.47 (+0.11), AAAP: 31.59 (+0.30), MACK: 5.82 (+0.02), PGNX: 5.84 (-0.01), BLCM: 16.04 (+0.16), CYCC: 5.01 (-0.02), RXDX: 5.52 (+0.01), MRK: 58.66 (unch), AZN: 33.84 (-0.30), JUNO: 30.86 (-0.07), CBLI: 2.48 (+0.01), NVS: 83.07 (-0.19), CELGZ: 1.14 (-0.02)

Epithelial Ovarian Cancer - Pipeline Review, H2 2015
M2 - Thu Dec 17, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/62vzjr/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 35 of the 60 Companies Featured in this Pipeline Review - AbbVie Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Bayer AG - Bionomics Limited - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Genor BioPharma Co., Ltd. - Glycotope GmbH - Hetero Drugs Limited - ImmunoGen, Inc. - Immunotope, Inc. - Incyte Corporation - Innate Immunotherapeutics Limited - Johnson & Johnson - Mabion SA - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mycenax Biotech Inc. - Novartis AG - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Prima BioMed Ltd. - Tesaro, Inc. For more information visit http://www.researchandmarkets.com/research/62vzjr/epithelial
PCYC: 261.25 (+1.70), TSRO: 95.15 (+1.91), CERU: 2.89 (unch), PFE: 37.31 (+0.42), INCY: 90.00 (-0.21), IMGN: 2.96 (+0.18), AMGN: 174.16 (+2.13), JNJ: 125.40 (+0.17), CLSN: 1.22 (-0.01), CLVS: 15.04 (+0.76), MRK: 58.66 (unch), AZN: 33.84 (-0.30), ABBV: 66.94 (+0.71), NVS: 83.07 (-0.19), XLRN: 34.40 (+0.48)

Merger & Acquisition ETFs: Will 2016 Replicate 2015?
Zacks Equity Research - Zacks Investment Research - Tue Dec 15, 11:50AM CST
ETFs to play the winning momentum of merger and acquisitions in 2015 globally.
PCYC: 261.25 (+1.70), BRCM: 54.67 (+0.17), PFE: 37.31 (+0.42), ABBV: 66.94 (+0.71), MNA: 28.52 (-0.01), NXPI: 84.23 (+0.14), FSL: 36.53 (-1.53), HSP: 89.95 (-0.01), AVGO: 163.51 (+1.53), CSMA: 20.50 (+1.27), MRGR: 36.15 (unch)

Ergomed Ups the Ante for CEL-SCI
ACCESSWIRE - Wed Oct 21, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 21, 2015 / Cancer immunotherapy company CEL-SCI Corp. (NYSE MKT: CVM) is thriving. Ergomed, a multinational Contract Research Organization (CRO) with a pristine reputation and the confidence in CEL-SCI's lead drug Multikine to make a huge upfront $10 million investment, recently raised the ante 20% - to $12 million. The deal was done under the same terms first put in place that calls for only a single-digit royalty on potential sales. This clearly shows Ergomed's confidence not only in the likelihood of Multikine being approved, but also in the large revenue potential of the cancer immunotherapy drug.
MNK: 67.37 (+0.03), INO: 10.42 (+0.54), SNTA: 0.34 (+0.07), PCYC: 261.25 (+1.70), ADRO: 14.84 (+0.16), CVM: 0.46 (+0.01), IMGN: 2.96 (+0.18), CLLS: 27.10 (+0.73), AEZS: 3.44 (+0.07), JUNO: 30.86 (-0.07), BMY: 76.19 (+1.38)

Hodgkin Lymphoma Pipeline Review, H2 2015 - 38 Companies & 57 Drug Profiles
M2 - Wed Sep 23, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5k9pd/hodgkin_lymphoma) has announced the addition of the "Hodgkin Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - 4SC AG - Acetylon Pharmaceuticals, Inc. - Actinium Pharmaceuticals, Inc. - ADC Therapeutics Sarl - Affimed Therapeutics AG - Aptose Biosciences Inc. - Arbutus Biopharma Corporation - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Biogenomics Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell Medica Limited - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - Curis, Inc. - Gamida Cell Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Johnson & Johnson - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - Molecular Templates Inc. - NantKwest, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Philogen S.p.A. - Seattle Genetics, Inc. - Selvita SA - Sigma-Tau S.p.A. - TG Therapeutics, Inc. - Theravectys SA Drug Profiles (Partial List) - abexinostat hydrochloride - Drug Profile - acalisib - Drug Profile - ADCT-301 - Drug Profile - AFM-13 - Drug Profile - Alocrest - Drug Profile - aNK Program - Drug Profile - APTO-253 - Drug Profile - azacitidine - Drug Profile - BMS-986016 - Drug Profile - BPX-501 - Drug Profile - brentuximab vedotin - Drug Profile - CBM-C30.1 - Drug Profile - Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile - Cell Therapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile - Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile - Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile - Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile - CMD-003 - Drug Profile - CPI-0610 - Drug Profile - CUDC-907 - Drug Profile - Dendritic Cell Therapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile - INCB-40093 - Drug Profile - Indimitecan - Drug Profile - Indotecan hydrochloride - Drug Profile - interferon alfa-2b (recombinant) - Drug Profile - Iomab-B - Drug Profile - NSC-678515 - Drug Profile - panobinostat - Drug Profile - pembrolizumab - Drug Profile - pevonedistat hydrochloride - Drug Profile - procarbazine hydrochloride - Drug Profile - radretumab - Drug Profile - Recombinant Proteins for Melanoma and Hodgkin's Lymphoma - Drug Profile - TGR-1202 - Drug Profile - TKM-PLK1 - Drug Profile For more information visit http://www.researchandmarkets.com/research/x5...n_lymphoma
CRIS: 1.74 (+0.06), PCYC: 261.25 (+1.70), PFE: 37.31 (+0.42), INCY: 90.00 (-0.21), TGTX: 5.79 (-0.12), BMY: 76.19 (+1.38), ABUS: 4.17 (+0.08), JNJ: 125.40 (+0.17), APTO: 2.51 (-0.01), ATNM: 1.71 (-0.07), BLCM: 16.04 (+0.16), SGEN: 49.22 (+1.16), GILD: 80.46 (+0.99), MRK: 58.66 (unch), AVEO: 0.99 (-0.01), MRTX: 4.75 (+0.11), CBMG: 14.82 (-0.07), NVS: 83.07 (-0.19), CELGZ: 1.14 (-0.02)

Global Nasopharyngeal Cancer Pipeline Review 2015
M2 - Tue Sep 08, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2qlv6j/nasopharyngeal) has announced the addition of the "Nasopharyngeal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ambrx, Inc. - AVEO Pharmaceuticals, Inc. - BioDiem Ltd - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Merck & Co., Inc. - Otsuka Holdings Co., Ltd. - Pharmacyclics, Inc. - Theravectys SA - Zhejiang BetaPharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2q...pharyngeal
PCYC: 261.25 (+1.70), CYCC: 5.01 (-0.02), AMBX: (), MRK: 58.66 (unch), AVEO: 0.99 (-0.01), GSK: 45.25 (+0.18), CELGZ: 1.14 (-0.02)

Pharmacyclics Up 77.4% Since SmarTrend Uptrend Call (PCYC)
Comtex SmarTrend(R) - Wed Jul 08, 11:30AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on January 13th, 2015 at $147.27. In approximately 6 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25.
PCYC: 261.25 (+1.70)

Uptrend Call Working As Pharmacyclics Stock Rises 77.4% (PCYC)
Comtex SmarTrend(R) - Wed Jul 01, 9:44AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on January 13th, 2015 at $147.27. In approximately 6 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25.
PCYC: 261.25 (+1.70)

Burkitt Lymphoma Therapeutics Pipeline Review, H1 2015 - 6 Companies & 10 Drug Profiles
M2 - Wed Jun 24, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/896pmt/burkitt_lymphoma) has announced the addition of the "Burkitt Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Constellation Pharmaceuticals, Inc. - Karyopharm Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Seattle Genetics, Inc. Drug Profiles - alisertib - AZD-6738 - denintuzumab mafodotin - ibrutinib - Monoclonal Antibody Conjugated to Target CD20 for Leukemia and Burkitt Lymphoma - selinexor - SH-7129 - SH-7133 - SH-7139 - Small Molecules to Inhibit BET for Cancer For more information visit http://www.researchandmarkets.com/research/89...t_lymphoma
PCYC: 261.25 (+1.70), SGEN: 49.22 (+1.16), AZN: 33.84 (-0.30), KPTI: 7.23 (-0.15)

Pharmacyclics Has Returned 77.4% Since SmarTrend Recommendation (PCYC)
Comtex SmarTrend(R) - Wed Jun 24, 9:19AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on January 13th, 2015 at $147.27. In approximately 5 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25.
PCYC: 261.25 (+1.70)

Pharmacyclics, Inc. (PCYC) - Financial and Strategic SWOT Analysis Review
M2 - Fri Jun 12, 3:54AM CDT

PCYC: 261.25 (+1.70)

T-Cell Leukemia Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2b68lm/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - iDD biotech SAS - Kyowa Hakko Kirin Co., Ltd. - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Sanofi - Stemline Therapeutics, Inc. - Theravectys S.A. - Tolero Pharmaceuticals, Inc. Drug Profiles - AGS-67E - alemtuzumab - Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - BMS-906024 - Cell Therapy to Target CD38 for cancer - IDD-003 - INA-01 - lenalidomide - MMIG-202 - mogamulizumab - Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - NK-314 - Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - PCI-34051 - PF-03084014 - SL-101 - Synthetic Peptide for Oncology and Male health - THV-02 - TP-0903 For more information visit http://www.researchandmarkets.com/research/2b...l_leukemia
PCYC: 261.25 (+1.70), PFE: 37.31 (+0.42), BMY: 76.19 (+1.38), STML: 7.40 (unch), CELGZ: 1.14 (-0.02)

Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
M2 - Wed Jun 10, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pl7hb/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - Calithera Biosciences, Inc. - Celgene Corporation - Genmab A/S - Gilead Sciences, Inc. - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nordic Nanovector AS - Novartis AG - Onyx Pharmaceuticals, Inc. - Pharmacyclics, Inc. Drug Profiles - ACP-196 - ARGX-110 - Betalutin - carfilzomib - CB-839 - copanlisib - DI-B4 - everolimus - FV-162 - FV-214 - GS-9973 - ibrutinib - idelalisib - IMO-8400 - INCB-39110 - INCB-40093 - IST-1097 - ixazomib citrate - lenalidomide - ofatumumab - oprozomib - pevonedistat hydrochloride - sapanisertib - selinexor - Small Molecules to Inhibit IRAK4 for Immunology and Oncology - spebrutinib besylate - venetoclax For more information visit http://www.researchandmarkets.com/research/8p...aldenstrom
PCYC: 261.25 (+1.70), INCY: 90.00 (-0.21), IDRA: 1.67 (-0.05), GILD: 80.46 (+0.99), CALA: 3.15 (-0.02), ABBV: 66.94 (+0.71), NVS: 83.07 (-0.19), CELGZ: 1.14 (-0.02), KPTI: 7.23 (-0.15)

Shares of PCYC Up 77.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jun 09, 11:25AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on January 13th, 2015 at $147.27. In approximately 5 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25.
PCYC: 261.25 (+1.70)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 18

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 76

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Inventor Launches Handy Solution for Kids' Car Sickness

Updated Category News Views 5

A Fresh Take on an Age-Old Problem Just when you thought the universe had thrown all it could at beleaguered parents, here comes a nifty little accessory tackling those dreaded uphill battles with kids and car rides. Some bright spark from Middleburgh, New York, sick of scrubbing car seats and clothing every other road trip, came up with a clever little invention named...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 73

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 56

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
AppLovin Faces Legal Heat: Investors on Edge Today

Updated Category News Views 43

AppLovin's Day of Reckoning: Investors Take Note Ever find yourself caught in a whirlwind of corporate promises that slide into disappointment? Well, buckle up, because that's exactly where AppLovin finds itself today. They've stirred up a storm with investors over some questionable hyperbole about their artificial intelligence tools and ad services. Missteps and Market...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 16

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading

Top 5 Most Recently Viewed Articles

PriceSmart Achieves Strong First Quarter Results and Expansion Plans

Updated Category News Views 229

PriceSmart Reports Impressive Growth in First Quarter of Fiscal 2026 PriceSmart, Inc. (NASDAQ: PSMT), with a presence across multiple regions, has announced substantial financial results for the first quarter of fiscal 2026, highlighting their ongoing growth and expansion strategies. The recent quarter ended on November 30, 2025, and the figures reflect a robust upward...

Continue Reading
Discover the New Belleza Community with Model Homes in California

Updated Category News Views 400

Exciting New Community in California Belleza at Lakeview is thrilled to announce the opening of their model homes, marking a significant step forward in the development of a brand new community in California. This community, designed with precision and style, invites potential homeowners to explore two stunning model homes, set to open soon for tours. Homebuyers are in...

Continue Reading
Bullish Nasdaq Signals Strong Potential for Long Investments

Updated Category News Views 89

Understanding Nasdaq's Recent Performance Recent market movements have highlighted a robust resurgence for bullish traders as they confidently regain control of their positions. The gains witnessed were particularly notable as the market showed resilience in defending critical support levels. Nasdaq's Bullish Technical Indicators As we explore the Nasdaq index, it becomes...

Continue Reading
Zero Homes Expands Services for Energy-Efficient Solutions

Updated Category News Views 123

Zero Homes Launches Comprehensive Services Across Colorado Zero Homes, a pioneering startup focused on digital solutions for home electrification, has announced its comprehensive statewide services tailored for every homeowner in Colorado. With its innovative approach, Zero Homes aims to guide residents in tapping into the newly established Colorado Home Energy Rebate...

Continue Reading
United Community Bank Foundation Commits $350,000 for Relief Aid

Updated Category News Views 107

United Community Bank Foundation's Commitment to Relief Efforts In the wake of the severe devastation caused by Hurricane Helene in the southern regions, the United Community Bank Foundation has stepped forward with a significant pledge. They are dedicating a remarkable amount of $350,000 to support local nonprofits that are actively engaged in the recovery and assistance...

Continue Reading